Abstract: Bevacizumab(BEV), a recombinant humanized anti-VEGF monoclonal antibody, represses the tumor angiogenesis by blocking the binding of VEGF to its receptors，thus to inhibit the growth of malignancies. Clinical studies have demonstrated that BEV is active as a single agent for recurrent ovarian cancer, and exhibits better efficacy when combines with cytotoxic drugs, such as taxane, pegylated liposomal doxorubicin, cyclophosphamide and so on. Moreover, BEV plays an important role in the management of malignant ascites caused by ovarian cancer and significantly improves the patients' quality of life. Therefore,BEV has broad prospects in the treatment of recurrent ovarian cancer.